microtubule associated protein tau

Home
Ligands
microtubule associated protein tau (Human)

GtoPdb Ligand ID: 9275

Compound class: Endogenous peptide in human, mouse or rat

Comment: The MAPT gene transcript undergoes complex, regulated alternative splicing. Different splice variants are expressed in different neurons and at different stages of neuronal maturation. The 757 amino acid isoform 1 contains three tau/MAP repeats which mediate tau interaction with tubulin (isoforms with four tau/MAP repeats are also reported).

MAPT gene polymorphisms are reported to predispose to neurodegenerative diseases including Alzheimer's disease (AD), Pick's disease [3-4,7] and frontotemporal dementia [5-6,11]. These types of conditions are known as tauopathies. The neurofibrillary tangles detected in AD brains are made up of pathologic paired helical filaments composed in large part of a truncated 100-amino-acid fragment of tau protein [10].

So far we have annotated three types of target relationships for tau protein:
1) aggregation antagonists/inhibitors (e.g. leucomethylthioninium)
2) imaging reagents for detection (e.g. flortaucipir (18F))
3) anti-tau monoclonal antibodies (e.g. zagotenemab)

In addition to zagotenemab, other clinical stage mAbs that target tau include gosuranemab (BMS-986168/BIIB092; for progressive supranuclear palsy PSP- development terminated, primary endpoint was not met in Phase 2), semorinemab (RO-7105705; for AD), tilavonemab (ABBV-8E12; for PSP and AD) and bepranemab (UCB0107; originally in development for PSP).

Species: Human